The analyst raised his price targets on coal andexploration and production E&P stocks by an average
The analyst raised his price targets on coal, andexploration and production (E&P) stocks by an average of 21percent. “We downgrade Encore as we now see peer average upside evenat a premium multiple to historical average,” Singer wrote in anote to clients. However, Singer downgraded Encore Acquisition Co EAC.N to”neutral” from “buy” and removed EOG Resources Inc (EOG.N) fromthe conviction buy list. “We expect the Street to better recognize DVN’s unbookedresource potential in key shale plays, oil sands, and deepwaterGulf of Mexico as oil/gas prices recover,” analyst Brian Singersaid. Stocks | Mexico Goldman raised Devon to “buy” from “neutral” and Anadarkoto “neutral” from “sell”.
May 11 (Reuters) – Goldman Sachs upgraded Devon Energy Corp(DVN.N) and Anadarko Petroleum Corp (APC.N), saying thecompanies would benefit from commodity price upside andexposure to shale plays. Eyal Leibovitz, CFO, +Copyright Business Wire 2009. EyalLeibovitz, CFO or – +972-8-940-6472KamadaMr. For additional information, please visit or contact Mr. The company has recently completed a Phase III clinical trial in the US with itsflagship IV Alpha-1 Antitrypsin (AAT) product indicated for treating AATdeficiency and is currently in advanced stages of development of its nextgeneration, inhaled administration AAT for the treatment of various lungdiseases including cystic fibrosis and bronchiectasis. Licensed and marketed in more than 15countries, several of these specialty therapeutics and are currently undergoingadvanced clinical trials.
About KamadaKamada is a public biopharmaceutical company (TASE:KMDA) developing, producingand marketing a line of specialty life-saving therapeutics using its proprietarychromatographic purification technologies. Ralf Hahn, Chairman of the Board and one of the controlling shareholders,and UDT Med Holdings LLC, New York. On May 4, 2009, Kamada closed on the sale of approximately US$7 million of itscommon stock in a private allocation to a select group of investors, includingMr. “We are pleased to report this transaction, which further enhances our capitalbase, represents a significant vote of confidence by a highly regarded,knowledgeable investment fund in Kamada and the Company`s prospects,” said DavidTsur, CEO of Kamada. The placement resulted in gross proceeds toKamada of approximately US$1.5 million. NESS ZIONA, Israel–(Business Wire)–Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development,production and marketing of specialty life-saving biotherapeutics announcedtoday that, pursuant to an agreement dated February 23, 2009, it has completedthe private allocation of the company`s common stock to Meitav, a leadinginstitutional investor in Israel. Soho Resources Corp.relies upon litigation protection for forward-looking statements.Shares Issued – 125,887,913Last Close 2009/05/08 C$0.125Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in the policiesof the TSX Venture Exchange) accepts responsibility for the adequacy oraccuracy of this release.Contacts:Soho Resources Corp.Glen Sandwell604.684.8071 or Toll Free: 2009, Market Wire, All rights reserved.-0-.